Y-mAbs Therapeutics, Inc. (YMAB)

Y-mAbs Therapeutics Revenue

Y-mAbs Therapeutics had revenue of $84.50M in the twelve months ending March 31, 2024, with 12.62% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $19.93M, a -1.58% decrease year-over-year. In the year 2023, Y-mAbs Therapeutics had annual revenue of $84.82M with 29.96% growth.

• Revenue (ttm): $84.50M
• Revenue Growth: +12.62%
• P/S Ratio: 5.90
• Revenue / Employee: $844,990
• Employees: 100
• Market Cap: 498.95M USD

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	84.82M	19.55M	29.96%
Dec 31, 2022	65.27M	30.37M	87.03%
Dec 31, 2021	34.90M	14.15M	68.18%
Dec 31, 2020	20.75M	-	-
Dec 31, 2019	0	-	-
Dec 31, 2018	0	-	-
Dec 31, 2017	0	-	-
Dec 31, 2016	0	-	-

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.